MRI, Neuropsychologic Tests Best Predicting Alzheimer’s Disease in Older Patients

The investigators came to this conclusion after analysis of data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), a large collaborative research project of medical centers in the United States and Canada. The researchers, from the University of Amsterdam (The Netherlands), divided the ADNI sample into two halves, a younger (< 75 years) and an older half (> 74 years). They showed that the cerebral spinal fluid (CSF) biomarkers (amyloid and tau), and fluorodeoxyglucose (FDG)- PET, are beneficial screening tools in the younger but not in the older patients.

In the older patients, MRI scans and neuropsychologic tests appeared to provide useful information, but CSF biomarkers and FDG-PET did not. The latter two techniques are informative only in younger patients. MRI scans and cognitive tests are not only helpful in differentiating patients who are already suffering from dementia from those who are not, but also in predicting who among older mild cognitive impairment (MCI) patients will progress to dementia within a few years. Predictions based on CSF biomarkers may turn out to be accurate in the longer term (5 or 10 years), in patients who live that long and become demented.

“But this long-term prediction is not what doctors, patients and families really need,” noted Willem A. van Gool, professor of neurology at the University of Amsterdam. “They want to know the causes of the symptoms, which made them seek help at a memory clinic, and they want to know what the prognosis is in a shorter time frame.”

From a theoretic point of view these results underscore that dementia in the older elderly is not exactly the same as Alzheimer’s disease in younger patients. It is in all probability a combination of disease processes. At older ages, vascular brain damage and degenerative processes other than amyloid accumulation, such as sclerosis of the hippocampus, are probably significant contributors to the dementia syndrome. “At any rate,” Prof. Van Gool said, “research findings stemming from relatively young patient samples cannot readily be extrapolated to the vast majority of older dementia patients. In older persons with dementia the causes are more complex than mere amyloid-beta accumulation, and researchers have to address this complexity.”

Dr. Ben Schmand, professor of clinical neuropsychology at the University of Amsterdam, cautioned a practical approach for clinicians. “In MCI patients,” he said, “particularly in older patients, it is not sufficient to base a diagnosis solely on a brief memory test, an MRI scan, and a lumbar puncture. Generally, a more thorough clinical evaluation will be necessary Cerebrospinal fluid biomarkers and PET scanning remain informative in relatively young patients.”

Related Links:
University of Amsterdam